Summary Reader's Response Draft 1
BiVACOR’s Total Artificial Heart (TAH), introduced on the website “Replacing Hearts. Restoring Lives.” (BiVACOR, n.d.), offers a groundbreaking long-term therapy for individuals facing severe biventricular heart failure. This solution caters to those in the late stages of heart failure, offering critical support while awaiting a heart transplant or in cases where transplantation is not feasible. The BiVACOR system comprises a rotor suspended using advanced magnetic levitation (MAGLEV), positioned between opposing pump enclosures. Its primary function is to assist both the left and right sides of the heart, made possible by impeller blades for each side attached to the revolving core. Activation of the core occurs through an electromagnetic motor and bearing configuration situated atop the pump enclosures, allowing precise control over circulation adjustment through a differential fluid discharge. With its revolutionary design and features, the introduction of BiVACOR’s Total Artificial Heart expands treatment avenues and provides extended hope to individuals experiencing heart failure.
In the article "Monash, Bivacor-Led Consortium to Develop and Commercialise World-First Durable Total Artificial Heart," it's highlighted that heart failure is a widespread global health challenge, impacting around 26 million people worldwide and growing more prevalent (AM News, 2021). The scarcity of available donor hearts emphasises the need for advanced mechanical circulatory support devices. Although left ventricular assist devices (LVADs) have seen increased use, addressing right heart dysfunction remains a persistent hurdle despite advancements. The options for providing lasting support to both sides of the heart are limited. Syncardia's total artificial heart is currently the primary approved device, although it has known limitations (Emmanuel et al., 2023). In this context, the emergence of BiVACOR's Total Artificial Heart (TAH) is a groundbreaking development, offering dual-sided cardiac support for individuals with biventricular heart failure. Unlike existing options, BiVACOR's TAH comprehensively aids both sides of the heart through advanced hydraulic systems, magnetic levitation, and rotation technologies. This innovation significantly improves durability, biocompatibility, and adaptability to patients' needs, establishing BiVACOR's TAH as a superior alternative for those with biventricular heart failure (AM News, 2021). This unique capability to provide dual-sided cardiac services represents a significant advancement, offering a comprehensive and long-term solution for individuals dealing with biventricular failure and broadening treatment possibilities for a wider range of cardiac conditions.
Unlike the conventional pulsatile-flow models, BiVACOR’s total artificial heart operates on a rotary blood pump technology that is seamlessly implanted into the body. By employing magnetic levitation (MAGLEV), the heart features left and right vanes forming a magnetically suspended double-sided centrifugal impeller as the sole moving component (“BIVACOR® awarded grant to advance artificial heart”2022). Notably, this design achieves pulsatile blood outflow without conventional valves or ventricle chambers, minimising blood damage and mechanical wear. Consequently, these attributes enhance the heart replacement's durability, reliability, and biocompatibility, culminating in a remarkably extended lifespan of approximately 10 years devoid of significant mechanical risks.
In contrast to models like Syncardia's Total Artificial Heart, typically conceived as temporary solutions until a transplant is available, BiVACOR's device stands as a much closer approximation to the natural functioning of a human heart. The heart’s adaptive blood flow output system, automatically adjusting to a patient’s physiology, facilitates an improved quality of life, including the ability to exercise at maximum output (Park, 2021). Beyond longevity, this innovation instils assurance and peace of mind in patients, presenting a smoother, less stressful path for those awaiting a transplant or a sustainable, long-term solution. Ultimately, it offers unwavering and consistent support, eliminating the constant worry associated with limited timeframes.
However, due to the innovative features, there’s unfamiliarity and limited long-term data, which may pose challenges in predicting and mitigating potential risks and optimising its long-term performances and safety. This lack of extensive data hampers our ability to accurately predict potential risks and optimise the device's long-term performance and safety. Since the BiVACOR Total Artificial Heart is a relatively recent project, rigorous research and monitoring over an extended period are imperative to comprehensively understand its capabilities and safety profile in various clinical scenarios. This necessity for further research and validation underscores the ongoing nature of this innovative venture, where long-term data will eventually reveal the true extent of its success and transformative potential in the realm of medical technology.
In conclusion, BiVACOR's revolutionary Total Artificial Heart provides extended cardiac support through its unique dual-sided function and continuous-flow mechanism. This marks a significant advancement in treatment options and instils hope for individuals with heart failure. However, its innovative nature calls for prudent consideration due to limited long-term data.
Resources:
Artificial hearts made from magnets and titanium could save many lives. BBC Science Focus Magazine. (n.d.). Retrieved September 27, 2023, from https://www.sciencefocus.com/news/artificial-hearts-made-from-magnets-and-titanium-could-save-many-lives
BiVACOR. (n.d.). BiVACOR. Retrieved September 18, 2023, from https://bivacor.com/
BioSpace. (2022, October 27). BIVACOR® awarded grant to advance development of External Controller for its total artificial heart. BioSpace. Retrieved September 27, 2023, from https://www.biospace.com/article/bivacor-awarded-grant-to-advance-development-of-external-controller-for-its-total-artificial-heart/
Emmanuel, S., Jansz, P., Iyer, A., Watson, A., Connellan, M., Granger, E., Robson, D., MacDonald, P., Timms, D., Nestler, F., & Ayre, P. (2023). (960) the future of biventricular mechanical circulatory support. The Journal of Heart and Lung Transplantation, 42(4). Retrieved September 27, 2023, from https://doi.org/10.1016/j.healun.2023.02.1071
News, A. (2021, June 16). Monash, bivacor-led consortium to develop and commercialise world-first durable total artificial heart. Australian Manufacturing. Retrieved September 27, 2023, from https://www.australianmanufacturing.com.au/monash-bivacor-led-consortium-to-develop-and-commercialise-world-first-durable-total-artificial-heart/
Park, A. (2021, May 20). Bivacor lands $22m to begin human trials of its magnetic artificial heart. Fierce Biotech. Retrieved September 27, 2023, from https://www.fiercebiotech.com/medtech/bivacor-lands-22m-venture-capital-and-nih-funds-to-begin-human-studies-artificial-heart
Comments
Post a Comment